Advances in Chronic Kidney Disease
Volume 11, Issue 2 , Pages 228-233, April 2004

Promise or peril? impact of the medicare drug benefit on the ESRD population

  • Mark E Williams

      Affiliations

    • Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
    • Corresponding Author InformationAddress correspondence to Mark E. Williams, MD, FACP, Harvard Medical School, 1 Joslin Place, Boston, MA 02215 USA

No abstract is available. To read the body of this article, please view the Full Text online.

 

PII: S1073-4449(04)00013-5

doi:10.1053/j.arrt.2004.02.002

Advances in Chronic Kidney Disease
Volume 11, Issue 2 , Pages 228-233, April 2004

Article Tools

* Image Usage & Resolution